Simon P. Kim

Simon P. Kim

Auto-generated profile, based on publicly available information

Simon P. Kim

Cleveland, OH

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2018 in Cancer
Verified
Journal Article
Open access
PDF file
UJUsama Jazzar
Usama Jazzar
SYShan Yong
Shan Yong
ZKZachary Klaassen
Zachary Klaassen
JHJin Huo
Jin Huo
BHByron D. Hughes
Byron D. Hughes
SWStephen B. Williams
Stephen B. Williams
BACKGROUND: Treatments for muscle‐invasive bladder cancer are multimodal, complex, and often carry significant risks of physical and psychological morbidity. The objectives of this study were to define the incidence and types of psychiatric illnesses diagnosed after treatment and to determine their impact on survival outcomes. METHODS: In total, 3709 patients who were diagnosed with clinical stage T2 through T4a bladder cancer from January 1, 2002, to December 31, 2011, from the Surveillance, Epidemiology, and End Results‐Medicare were analyzed. Multivariable analysis and Cox proportional‐hazards models were used to determine the predictors associated with psychiatric diagnosis and impact on survival outcomes. RESULTS: Of 3709 patients, 1870 (50.4%) were diagnosed with posttreatment psychiatric disorders. Patients who underwent radical cystectomy were identified as being at significantly greater risk of having a posttreatment psychiatric illness compared with those who received radiotherapy and/or chemotherapy (hazard ratio [HR], 1.19; 95% confidence interval [CI], 1.07‐1.31; P = .001). In adjusted analyses, diagnosis of a psychiatric disorder resulted in significantly worse overall survival (HR, 2.80; 95% CI, 2.47‐3.17; P < .001) and cancer‐specific survival (HR, 2.39; 95% CI, 2.05‐2.78; P < .001). CONCLUSIONS: One‐half of patients with muscle‐invasive bladder cancer who underwent treatment were diagnosed with a psychiatric disorder, which resulted in worse survival outcomes compared with patients who did not have a posttreatment psychiatric diagnosis. This information can be used to inform interventions to educate patients with muscle‐invasive bladder cancer regarding the impact of different treatments on mental health. Cancer 2018 . © 2018 American Cancer Society .

1 January 2021 in European Urology Focus
Verified
Journal Article
Closed access
SKSimon P. Kim
Simon P. Kim
RKR. Jeffrey Karnes
R. Jeffrey Karnes
RMRaphael Mwangi
Raphael Mwangi
HHHolly Van Houten
Holly Van Houten
CGCary P. Gross
Cary P. Gross
NSNilay D. Shah
Nilay D. Shah

1 September 2016 in BJU International
Verified
Journal Article
Closed access
PDF file
MMMatthew J. Maurice
Matthew J. Maurice
MBMatthew J. Bream
Matthew J. Bream
SKSimon P. Kim
Simon P. Kim
RARobert Abouassaly
Robert Abouassaly

18 January 2017 in Cancer
Verified
Journal Article
Open access
PDF file
SWStephen B. Williams
Stephen B. Williams
JHJin Huo
Jin Huo
KCKarim Chamie
Karim Chamie
MSMarc C. Smaldone
Marc C. Smaldone
CKChristopher D. Kosarek
Christopher D. Kosarek
BCBrian F. Chapin
Brian F. Chapin
BACKGROUND: The objective of this study was to compare the overall survival of patients who undergo radical prostatectomy or radiotherapy versus noncancer controls to discern whether there is a survival advantage according to prostate cancer treatment and the impact of selection bias on these results.METHODS: A matched cohort study was performed using the Surveillance, Epidemiology, and End Results (SEER)‐Medicare–linked database. In total, 34,473 patients ages 66 to 75 years were identified who were without significant comorbidity, were diagnosed with localized prostate cancer, and received treatment treated with surgery or radiotherapy between 2004 and 2011. These patients were matched to a noncancer control cohort. The rates of all‐cause mortality that occurred within the study period were compared. Cox proportional hazards regression analysis was used to identify determinants associated with overall survival.RESULTS: Of 34,473 patients who were included in the analysis, 21,740 (63%) received radiation therapy, and 12,733 (37%) underwent surgery. There was improved survival in patients who underwent surgery (hazard ratio, 0.35; 95% confidence interval, 0.32‐0.38) and in those who received radiotherapy (hazard ratio, 0.72; 95% confidence interval, 0.68‐0.75) compared with noncancer controls. Overall survival improved significantly in both treatment groups, with the greatest benefit observed among patients who underwent surgery (log rank P < .001).CONCLUSIONS: Population‐based data indicated that patients with prostate cancer who received treatment with either surgery or radiotherapy had improved overall survival compared with a cohort of matched noncancer controls. Surgery produce longer survival compared with radiation therapy. These results suggest an inherent selection‐bias because of unmeasured confounding variables. Cancer 2017;123:1617–1624. © 2017 American Cancer Society.

1 March 2013 in Current Opinion in Urology
Verified
Journal Article
Closed access
SKSimon P. Kim
Simon P. Kim
RTR. Houston Thompson
R. Houston Thompson
With clinical guidelines recommending partial nephrectomy for small renal masses, it is essential to understand the benefits of partial nephrectomy in regards to renal function. Our objective was to review current evidence and highlight emerging issues for partial nephrectomy and renal function. A recent clinical trial of partial and radical nephrectomy found minimal differences in survival or adverse renal sequelae. However, most observational studies and systematic reviews suggest that partial nephrectomy decreases the risks of adverse renal function, in particular, new-onset severe chronic kidney disease, and improves overall survival. Key features associated with long-term renal function include treatment modality (observation, ablation, surgery), ischemia type and duration, amount of healthy renal preservation, and baseline renal function. Partial nephrectomy should remain the standard of care for small renal masses, if the renal tumor size and complexity are amenable to such a surgical approach. Efforts to minimize ischemia time are important for long-term renal functional recovery, and hypothermia should be considered if longer warm ischemia times are anticipated (i.e. >25 min). Although the preliminary results of zero ischemia partial nephrectomy are promising, further research is needed to determine if these surgical techniques are safely adaptable in the broader urologic community.

5 May 2017 in Cancer Causes & Control
Verified
Journal Article
Open access
PDF file
SWStephen B. Williams
Stephen B. Williams
JHJin Huo
Jin Huo
CKChristopher D. Kosarek
Christopher D. Kosarek
KCKarim Chamie
Karim Chamie
SRSelwyn O. Rogers
Selwyn O. Rogers
Ashish M. KamatAshish M. Kamat
Ashish M. Kamat
Purpose Radical cystectomy is a surgical treatment for recurrent non-muscle-invasive and muscle-invasive bladder cancer; however, many patients may not receive this treatment. Methods A total of 27,578 patients diagnosed with clinical stage I–IV bladder cancer from 1 January 2007 to 31 December 2013 were identified from the Surveillance, Epidemiology, and End Results (SEER) registry database. We used multivariable regression analyses to identify factors predicting the use of radical cystectomy and pelvic lymph node dissection. Cox proportional hazards models were used to analyze survival outcomes. Results A total of 1,693 (6.1%) patients with bladder cancer underwent radical cystectomy. Most patients (92.4%) who underwent radical cystectomy also underwent pelvic lymph node dissection. When compared with white patients, non-Hispanic blacks were less likely to undergo a radical cystectomy [odds ratio (OR) 0.79, 95% confidence interval (CI) 0.64–0.96, p = 0.019]. Moreover, recent year of surgery 2013 versus 2007 (OR 2.32, 95% CI 1.90–2.83, p < 0.001), greater percentage of college education ≥36.3 versus <21.3% (OR 1.23, 95% CI 1.04–1.44, p = 0.013), Midwest versus West (OR 1.64, 95% CI 1.39–1.94, p < 0.001), and more advanced clinical stage III versus I (OR 29.1, 95% CI 23.9–35.3, p < 0.001) were associated with increased use of radical cystectomy. Overall survival was improved for patients who underwent radical cystectomy compared with those who did not undergo a radical cystectomy (hazard ratio 0.88, 95% CI 0.80–0.97, p = 0.008). Conclusion There is significant underutilization of radical cystectomy in patients across all age groups diagnosed with bladder cancer, especially among older, non-Hispanic black patients.